South Africa will introduce a new lenacapavir injection. This twice-yearly shot is for HIV prevention. It will be in select public clinics by April 2026. This marks a big step forward for the nation. It offers a great alternative to daily pills. However, another injectable, cabotegravir, is stalled. It had a four-year head start. The availability of a new HIV…
Tag: cabotegravir
-
HIV Prevention Injection Changes the Game in Treatment
South Africa will introduce a groundbreaking twice-yearly HIV prevention injection, lenacapavir, in select public clinics by April 2026. This move marks a significant step forward in the nation’s fight against HIV, offering a highly effective and convenient alternative to daily pills. However, this progress comes as another long-acting injectable, cabotegravir (CAB-LA), remains stalled despite having a four-year head start. The…
-
New HIV prevention shot promises six months of protection
A new injection containing the antiretroviral drug lenacapavir has demonstrated highly effective results in preventing HIV infection for six months per shot. The findings, announced by pharmaceutical company Gilead, mark a significant improvement over the current two-month protection offered by the long-acting cabotegravir (CAB-LA) injection. Lenacapavir, part of a new class of antiretroviral drugs called capsid inhibitors, works by interfering…